Literature DB >> 10450252

Treatment of schizoaffective disorder and schizophrenia with mood symptoms.

D F Levinson1, C Umapathy, M Musthaq.   

Abstract

OBJECTIVE: Patients with concurrent schizophrenic and mood symptoms are often treated with antipsychotics plus antidepressant or thymoleptic drugs. The authors review the literature on treatment of two overlapping groups of patients: those with schizoaffective disorder and those with schizophrenia and concurrent mood symptoms.
METHOD: MEDLINE searches (from 1976 onward) were undertaken to identify treatment studies of both groups, and references in these reports were checked. Selection of studies for review was based on the use of specified diagnostic criteria and of parallel-group, double-blind design (or, where few such studies addressed a particular issue, large open studies). A total of 18 treatment studies of schizoaffective disorder and 15 of schizophrenia with mood symptoms were selected for review.
RESULTS: For acute exacerbations of schizoaffective disorder or of schizophrenia with mood symptoms, antipsychotics appeared to be as effective as combination treatments, and there was some evidence for superior efficacy of atypical antipsychotics. There was evidence supporting adjunctive antidepressant treatment for schizophrenic and schizoaffective patients who develop a major depressive syndrome after remission of acute psychosis, but there were mixed results for treatment of subsyndromal depression. There was little evidence to support adjunctive lithium for depressive symptoms and no evidence concerning its use for manic symptoms in patients with schizophrenia.
CONCLUSIONS: Empirical data suggest that both groups of patients are best treated by optimizing antipsychotic treatment and that atypical antipsychotics may prove to be most effective. Adjunctive antidepressants may be useful for patients with major depression who are not acutely ill. Careful longitudinal assessment is required to ensure identification of primary mood disorders.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10450252     DOI: 10.1176/ajp.156.8.1138

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  27 in total

1.  A study of treatment outcomes from atypical antipsychotic medications in the Virginia public system of community care.

Authors:  David M Ziegler; Thomas J Peachey
Journal:  Community Ment Health J       Date:  2003-04

2.  Is schizoaffective disorder a stable diagnostic category: a retrospective examination.

Authors:  Patricia M Averill; Deborah L Reas; Andrew Shack; Nurun N Shah; Katherine Cowan; Kenneth Krajewski; Charles Kopecky; Robert W Guynn
Journal:  Psychiatr Q       Date:  2004

Review 3.  Elderly patients with schizophrenia and depression: diagnosis and treatment.

Authors:  Kandi Felmet; Sidney Zisook; John W Kasckow
Journal:  Clin Schizophr Relat Psychoses       Date:  2011-01

Review 4.  Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data.

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04       Impact factor: 5.270

Review 5.  Antipsychotic Management of Schizoaffective Disorder: A Review.

Authors:  Jean-Pierre Lindenmayer; Amandeep Kaur
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

6.  Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.

Authors:  Donald E Addington; Somaia Mohamed; Robert A Rosenheck; Sonia M Davis; Thomas Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Jeffrey A Lieberman
Journal:  J Clin Psychiatry       Date:  2010-09-21       Impact factor: 4.384

Review 7.  Postpsychotic depression in schizophrenia patients.

Authors:  Christian G Kohler; Elise A Lallart
Journal:  Curr Psychiatry Rep       Date:  2002-08       Impact factor: 5.285

Review 8.  Co-occurring depressive symptoms in the older patient with schizophrenia.

Authors:  John W Kasckow; Sidney Zisook
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

9.  Role of paliperidone extended-release in treatment of schizoaffective disorder.

Authors:  Carla M Canuso; Ibrahim Turkoz; Dong Jing Fu; Cynthia A Bossie
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

10.  Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.

Authors:  Pierre Chue
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.